A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)
Reason given: Business reason, unrelated to product safety
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Takeda
- Trial code
- NCT05863819
- Record updated
- 18 October 2023
- Original description
The main aim of this study is to learn about the time from start of mobocertinib to end of treatment with mobocertinib for any reason in Chinese adults with lung cancer who carry a certain gene mutation (epidermial growth factor receptor - EGFR exon 20 insertion mutation) during normal clinical practice.Read full original descriptionShow less
Effectiveness and Safety of Mobocertinib in Patients With EGFR Exon 20 Insertion NSCLC in Routine Clinical Practice in China: A Prospective, Single-arm, Multicenter, Observational Study
The main aim of this study is to learn about the time from start of mobocertinib to end of treatment with mobocertinib for any reason in Chinese adults with lung cancer who carry a certain gene mutation (epidermial growth factor receptor - EGFR exon 20 insertion mutation) during normal clinical practice.
Participants will be treated with mobocertinib as per their normal routine. Data for this study will be collected from the available medical records of a participant.
Inclusion: Participants with histologically/cytologically confirmed diagnosis of EGFR ex20ins positive locally advanced or metastatic NSCLC by local hospitals; Participants who received mobocertinib as treatment therapy in routine clinical practice; the decision to treat with mobocertinib had to be made independently by physician before enrollment into the study; The decision to treat a participant with mobocertinib had to be made independently by physician before enrollment into the study.
Exclusion: Participants who are participating in other NSCLC interventional clinical study during the treatment of mobocertinib in this study will be excluded; Other situations that the investigators consider not suitable for participation in this study.